The company will start three phase 3 trials of its G12D project this year.

But PFS data are lacking, and there are questions about first and second-line plans.

Early Ibtrozi sales and a low-cost licensing deal with Eisai disappoint investors.

Things look grim for Atara, which had been relying on a milestone from Pierre Fabre.

The company secures funding to push its lead candidate towards US approval.

Prexasertib data worsen again, and biomarkers are up in the air.